These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 12627501

  • 21. Hormone therapy and breast cancer: what factors modify the association?
    Gertig DM, Fletcher AS, English DR, Macinnis RJ, Hopper JL, Giles GG.
    Menopause; 2006; 13(2):178-84. PubMed ID: 16645531
    [Abstract] [Full Text] [Related]

  • 22. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.
    Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E.
    Eur J Cancer; 2013 Jan; 49(1):52-9. PubMed ID: 22892060
    [Abstract] [Full Text] [Related]

  • 23. Breast cancer risk in the WHI study: the problem of obesity.
    Kuhl H.
    Maturitas; 2005 May 16; 51(1):83-97. PubMed ID: 15883113
    [Abstract] [Full Text] [Related]

  • 24. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations.
    Schneider C, Jick SS, Meier CR.
    Climacteric; 2009 Dec 16; 12(6):514-24. PubMed ID: 19905903
    [Abstract] [Full Text] [Related]

  • 25. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment.
    Ursic-Vrscaj M, Bebar S.
    Eur J Surg Oncol; 1999 Apr 16; 25(2):146-51. PubMed ID: 10218456
    [Abstract] [Full Text] [Related]

  • 26. Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older.
    Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, Olafsson O, Tryggvadottir L.
    Acta Oncol; 2014 Jun 16; 53(6):752-8. PubMed ID: 24460068
    [Abstract] [Full Text] [Related]

  • 27. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J, HABITS Study Group.
    J Natl Cancer Inst; 2008 Apr 02; 100(7):475-82. PubMed ID: 18364505
    [Abstract] [Full Text] [Related]

  • 28. The risk of breast cancer after estrogen and estrogen-progestin replacement.
    Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C.
    N Engl J Med; 1989 Aug 03; 321(5):293-7. PubMed ID: 2546079
    [Abstract] [Full Text] [Related]

  • 29. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU, Einarsdóttir K, Friman EI, Wedrén S, Dickman PW, Hall P, Magnusson C.
    Cancer Epidemiol Biomarkers Prev; 2006 Dec 03; 15(12):2482-8. PubMed ID: 17164374
    [Abstract] [Full Text] [Related]

  • 30. Risk of stroke and hormone replacement therapy. A prospective cohort study.
    Li C, Engström G, Hedblad B, Berglund G, Janzon L.
    Maturitas; 2006 Apr 20; 54(1):11-8. PubMed ID: 16321486
    [Abstract] [Full Text] [Related]

  • 31. Breast cancer risk with postmenopausal hormonal treatment.
    Collins JA, Blake JM, Crosignani PG.
    Hum Reprod Update; 2005 Apr 20; 11(6):545-60. PubMed ID: 16150813
    [Abstract] [Full Text] [Related]

  • 32. Progestagen-only treatment before menopause: increased risk of breast cancer.
    Prescrire Int; 2008 Dec 20; 17(98):243. PubMed ID: 19422175
    [Abstract] [Full Text] [Related]

  • 33. Hormone replacement treatment and breast cancer risk: an age-specific analysis.
    Tavani A, Braga C, La Vecchia C, Negri E, Franceschi S.
    Cancer Epidemiol Biomarkers Prev; 1997 Jan 20; 6(1):11-4. PubMed ID: 8993791
    [Abstract] [Full Text] [Related]

  • 34. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study.
    Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, Davidson R, Izatt L, Cole T, Noguès C, Luporsi E, Huiart L, Hoogerbrugge N, Van Leeuwen FE, Osorio A, Eyfjord J, Radice P, Goldgar DE, Easton DF, Epidemiological Study of Familial Breast Cancer (EMBRACE), Gene Etude Prospective Sein Ovaire (GENEPSO), Genen Omgeving studie van de werkgroep Hereditiair Borstkanker Onderzoek Nederland (GEO-HEBON), International BRCA1/2 Carrier Cohort Study (IBCCS) collaborators group.
    Cancer Epidemiol Biomarkers Prev; 2007 Apr 20; 16(4):740-6. PubMed ID: 17416765
    [Abstract] [Full Text] [Related]

  • 35. Cancer issues.
    Marsden J, Sturdee D.
    Best Pract Res Clin Obstet Gynaecol; 2009 Feb 20; 23(1):87-107. PubMed ID: 19036643
    [Abstract] [Full Text] [Related]

  • 36. Menstrual factors in relation to breast cancer risk.
    Titus-Ernstoff L, Longnecker MP, Newcomb PA, Dain B, Greenberg ER, Mittendorf R, Stampfer M, Willett W.
    Cancer Epidemiol Biomarkers Prev; 1998 Sep 20; 7(9):783-9. PubMed ID: 9752986
    [Abstract] [Full Text] [Related]

  • 37. The risk of breast cancer linked to menopausal hormone therapy.
    Sæther S, Bakken K, Lund E.
    Tidsskr Nor Laegeforen; 2012 Jun 12; 132(11):1330-4. PubMed ID: 22717857
    [Abstract] [Full Text] [Related]

  • 38. [Replacement therapy in menopause and risk for breast tumors].
    Franceschi S.
    Ann Ist Super Sanita; 1997 Jun 12; 33(2):207-11. PubMed ID: 9470242
    [Abstract] [Full Text] [Related]

  • 39. [Increased risk of breast cancer following hormone replacement therapy during climacteric. 3 440 extra cases might have been caused by the treatment in Sweden during the 1990s].
    Magnusson C, Reeves G.
    Lakartidningen; 1997 Jun 12; 102(16):1228-30. PubMed ID: 15921095
    [No Abstract] [Full Text] [Related]

  • 40. Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis.
    Garbe E, Levesque L, Suissa S.
    Maturitas; 2004 Mar 15; 47(3):175-83. PubMed ID: 15036487
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.